OPM announces its 2024 annual results and clinical developments

OPM announces its 2024 annual results and clinical developments

Dijon, France, April 3, 2025, at 6:00 pm CEST – Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces its 2024 financial results, approved by the Board of Directors on April 3, 2025.